Former US President Donald Trump has announced a new tariff policy aimed at encouraging pharmaceutical companies to shift generic drug manufacturing to the United States.
According to Trump's statement, all generic drugs imported into the US will continue to attract 0% tariff for the next two years, starting from August 1, 2026. After this transition period, the tariff structure will change significantly.
Key Highlights
- 0% tariff on imported generic drugs for the first 2 years (effective August 1, 2026).
- Tariff to increase to 100% for the following one year.
- Thereafter, the tariff will rise to 200%.
- Objective is to reshore generic pharmaceutical manufacturing to the United States.
- Companies that do not establish manufacturing facilities in the US during the transition period could face significantly higher import costs.
- The policy will not impact patented, branded, or innovative drugs, which will continue under the existing framework.
Trump stated that the policy is designed to encourage pharmaceutical companies to set up manufacturing plants and equipment within the United States, reducing dependence on overseas production and strengthening domestic pharmaceutical capacity.
Former US President Donald Trump ne generic drugs ko lekar ek bada tariff plan announce kiya hai, jiska objective pharmaceutical manufacturing ko America mein wapas lana (reshoring) aur imported medicines par dependency ko kam karna hai.
Key Highlights
- 1 August 2026 se imported generic drugs par 2 saal tak 0% tariff rahega.
- Uske baad 1 saal ke liye 100% tariff lagaya jayega.
- Iske baad tariff 200% tak badh jayega.
- Policy ka main objective generic drug manufacturing ko US ke andar shift karna hai.
- Jo companies transition period ke dauran US mein manufacturing plant nahi lagayengi, unhe higher tariffs ka saamna karna pad sakta hai.
- Patented, branded aur innovative drugs par is policy ka koi asar nahi hoga.
Trump ke mutabik, is policy ka maksad pharmaceutical companies ko America mein naye manufacturing plants aur facilities establish karne ke liye encourage karna hai. Isliye pehle do saal tak imported generic medicines par zero tariff rakha gaya hai, taaki companies ko apni manufacturing US mein shift karne ka samay mil sake.